Clínicos
A adição de microesferas de resina SIR-Spheres® Y-90 à quimioterapia aumentou significativamente a taxa de resposta no fígado em todos os pacientes, como mostrado anteriormente também no estudo SIRFLOX.
bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)
Gibbs P et al. Clin Col Cancer 2018 Jun 12 ePub: doi: 10.1016/j.clcc.2018.06.001.
Compte-tenu de la règlementation en France, le contenu de ce site n’est pas accessible sur le territoire français.
En cliquant « Oui / Yes », vous confirmez que vous n’accédez pas ce site du territoire français.
En cliquant sur « Quitter / Exit », vous serez dirigé vers un autre site web.
Due to regulations in France, the content of this website can only be accessed from outside the French territory.
By clicking « Oui / Yes » you are confirming that you are not accessing the site from the French territory.
By clicking on « Quitter / Exit », you will be directed away from this site.
You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.
Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.
Click 'Continue' to proceed to the third-party Web site.
You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.
Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes
no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.
By clicking "Continue" you are confirming that you are a journalist. If you are not a journalist, then please click on Sirtex logo which will direct you to the Sirtex homepage.
The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region.
Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.
Click 'Continue' to proceed to the other Sirtex region Web site.
SIR-Spheres will have the following indication for use:
SIR-Spheres Y 90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.
SIR-Spheres will have the following indication for use:
SIR-Spheres Y 90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.
Click here to view our Technical Bulletin.
.By clicking “Continue” you are confirming that you are a Healthcare Professional. If you are not a Healthcare Professional, please click on Sirtex logo which will direct you to the Sirtex homepage.